Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Hemogenyx Pharmaceuticals (OTC:HOPHF) announced on March 31, 2026 completion of the manufacturing tech transfer for HG-CT-1 to Made Scientific and submission of a comparability data package to the FDA. The company is ready to recruit adults at the second, increased dose and begin pediatric recruitment at the lowest dose level.
This expands the Phase 1 R/R AML program and confirms cross-site manufacturing reproducibility.
Hemogenyx Pharmaceuticals (LSE:HEMO / OTC:HOPHF) announced its total issued share capital and voting rights as of 27 February 2026. The Company reported 6,425,429 ordinary shares, none held in treasury, so the total voting rights equal 6,425,429.
Shareholders may use this figure as the denominator to assess FCA Disclosure Guidance and Transparency Rules notification obligations.
Hemogenyx Pharmaceuticals (HOPHF) received notices to exercise warrants over 50,841 new ordinary shares at exercise prices between 180p and 350p, raising £118,632.
Application will be made for the Warrant Shares to be admitted to trading, expected at 8:00 a.m. on 27 February 2026. Upon Admission the total issued shares and voting rights will be 6,425,429.
Hemogenyx Pharmaceuticals (OTC:HOPHF) announced a corrected equity issue: a direct subscription of 333,333 new ordinary shares at £7.50 each, raising £2,500,000, with three‑year one‑for‑one warrants at £9.00. Enlarged share capital will be 6,374,588 ordinary shares after Admission.
Net proceeds will primarily fund continuation and dose escalation of the Phase I HG‑CT‑1 trials in adults and initiation in pediatric patients, following a DSMB positive recommendation and FDA pediatric clearance; manufacturing has been outsourced to MADE.
Hemogenyx Pharmaceuticals (HOPHF) raised £2,500,000 via a direct subscription of 313,333 ordinary shares at £7.50 each, with three‑year one‑for‑one warrants at £9. Proceeds will primarily fund continuation of the Phase I HG‑CT‑1 trials in adult and paediatric R/R AML.
The DSMB gave a positive recommendation in October 2025 to escalate the adult dose, and the FDA cleared a Phase I paediatric study for ages 12–18. Admission of the placing shares is expected on or around 13 February 2026, bringing the enlarged share capital to 6,354,588 ordinary shares.
Hemogenyx Pharmaceuticals (OTC: HOPHF) announced an update on the admission of new ordinary shares. The FCA has scheduled the admission hearing for 5 January 2026, with admission expected on or around 6 January 2026 at 08:00.
All other details from the company’s 18 December 2025 announcement remain unchanged.
Hemogenyx Pharmaceuticals (HOPHF) issued and allotted an aggregate of 123,377 new ordinary shares on 18 December 2025 arising from warrant exercises, RSU vesting and a deed of variation.
- Warrant shares: 105,556 shares exercised at £1.80 raising £190,000.
- RSU shares: 6,000 shares issued on vesting.
- Variation shares: 11,821 shares issued at £8.84 under a 16 September 2025 deed of variation.
Admission to FCA official list and LSE main market is expected around 08:00 on 23 December 2025. Total issued shares and voting rights on admission will be 6,041,255.
Hemogenyx Pharmaceuticals (HOPHF) published a Prospectus for the admission of 116,982 new ordinary shares on conversion of convertible loan notes and 439,629 new ordinary shares on exercise of warrants (together 556,611 New Ordinary Shares) to the equity shares (transition) category of the FCA Official List and to trading on the Main Market of the London Stock Exchange.
Admission is expected to become effective and unconditional, and dealings in the New Ordinary Shares are expected to commence on 24 November 2025. The Prospectus is available at the company's registered office and online at https://hemogenyx.com, and will be submitted to the National Storage Mechanism for inspection.
Hemogenyx Pharmaceuticals (HOPHF) announced that an independent DSMB has cleared its Phase I CAR-T candidate HG-CT-1 to escalate to the next adult dose cohort after reviewing safety data from the first three patients, with no dose-limiting toxicities observed.
The clearance also permits initiation of pediatric recruitment at the same lowest dose used in adults. The Phase I trial evaluates safety, tolerability and preliminary efficacy with secondary endpoints including AML-specific responses, progression-free survival, duration of response and overall survival. The company also granted 6,000 Restricted Share Units to key team members under existing equity incentive arrangements.
Hemogenyx Pharmaceuticals (HOPHF) announced on October 6, 2025 that the Institutional Review Board at MD Anderson Cancer Center approved an amendment to its Phase I HG-CT-1 clinical protocol to include children and adolescents with relapsed or refractory acute myeloid leukemia (R/R AML).
The PR states this expansion builds on safety and early efficacy signals observed in adult participants and allows the company to begin pediatric enrolment in the HG-CT-1 trial; the company says it will provide further updates as adult and pediatric enrolment progresses.